We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Early Immunogenicity Risk Mitigation
Poster

Early Immunogenicity Risk Mitigation

Early Immunogenicity Risk Mitigation
Poster

Early Immunogenicity Risk Mitigation

The ability of a drug candidate to induce an unwanted immune response can be a significant hurdle during drug development and a reason for product failures. Unwanted immunogenicity can cause loss of efficacy, altered pharmacodynamics and stability problems.

Implementing early immunogenicity assessment strategies using tools like in silico T cell epitope prediction and in vitro T cell assays can contribute significantly to the successful outcome of drug development programs and reduce the number of product failures.
Advertisement